60
Participants
Start Date
June 30, 2015
Primary Completion Date
October 31, 2016
Study Completion Date
October 31, 2016
8 weeks SOF/LED
Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
12 weeks SOF/LED
Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are not treatment naïve or have cirrhosis will be assigned to 12 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
Digestive Health Associates, Plano
Liver and Digestive Consultants, Houston
Stanford University Medical Center, Palo Alto
San Jose Gastroenterology, San Jose
Collaborators (1)
Gilead Sciences
INDUSTRY
Stanford University
OTHER